Burkina Faso

Reimbursed Care Access

Burkina Faso maintains a strict national drug control regime under a domestic Code des Drogues that criminalizes production, possession, distribution and use of substances listed as narcotics or psychotropics. Medical use of commonly used anesthetic agents such as ketamine is documented in hospital supply lists, but there is no regulatory pathway, national reimbursement program, or known approval for spiraling psychedelic therapeutics (psilocybin, MDMA, or new branded products such as esketamine) for psychiatric indications in the country. For virtually all classic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) access is limited to authorized research (if any) or is otherwise prohibited under criminal provisions of the national drug code.